Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.32 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007396 | 1.00 | SRD5A2 (0.36) | SRD5A2ARPGRNR3C2LMNA | |
| SCHEMBL2324082 | 0.92 | SRD5A2 (0.35) | SRD5A2ARPGRNR3C2 | |
| SCHEMBL12446650 | 0.86 | SRD5A2 (0.39) | SRD5A2ARPGRNR3C2LMNA | |
| SCHEMBL9222958 | 0.81 | SRD5A2 (0.49) | SRD5A2 | |
| SCHEMBL3356468 | 0.81 | SRD5A2 (0.49) | SRD5A2 | |
| SCHEMBL923303 | 0.79 | SRD5A2 (0.36) | SRD5A2 | |
| SCHEMBL12904870 | 0.79 | SRD5A2 (0.36) | SRD5A2 | |
| SCHEMBL13333281 | 0.79 | SRD5A2 (0.36) | SRD5A2 | |
| SCHEMBL13797597 | 0.79 | SRD5A2 (0.36) | SRD5A2 | |
| SCHEMBL4102408 | 0.77 | SRD5A2 (0.39) | SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0201452-B1 | PROCESS FOR THE PREPARATION OF 17-ALPHA-ETHYNYL-17-BETA-HYDROXY-18-METHYL-ESTRA-4,15-DIEN-3-ONE AND THE STARTING PRODUCTS FOR THIS PROCESS | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-08-09 | — | — | EP | claimed |
| US-4719054-A | Process for the production of 17α-ethynyl-17β-hydroxy-18-methyl-4,15-estradien-3-one, and novel 3,5-estradien-17-one starting compounds for this process | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-01-12 | — | — | US | claimed |
| EP-0201452-A2 | Process for the preparation of 17-alpha-ethynyl-17-beta-hydroxy-18-methyl-estra-4,15-dien-3-one and the starting products for this process | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-11-12 | — | — | EP | claimed |
| JP-7316184-A | — | — | None | — | — | JP | disclosed |
| US-9012667-B2 | Process for introducing a double bond into position 15, 16 of a steroid | LABORATOIRE THERAMEX (MC) | 2015-04-21 | — | — | US | disclosed |
| EP-2534165-B1 | A PROCESS FOR INTRODUCING A DOUBLE BOND INTO POSITION 15,16 OF A STEROID | THERAMEX (MC) | 2013-07-24 | — | — | EP | disclosed |
| US-20130137885-A1 | PROCESS FOR INTRODUCING A DOUBLE BOND INTO POSITION 15, 16 OF A STEROID | LABORATOIRE THERAMEX (MC) | 2013-05-30 | — | — | US | disclosed |
| EP-2534165-A2 | A PROCESS FOR INTRODUCING A DOUBLE BOND INTO POSITION 15,16 OF A STEROID | Laboratoire Theramex (MC) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011098439-A2 | A PROCESS FOR INTRODUCING A DOUBLE BOND INTO POSITION 15,16 OF A STEROID | LABORATOIRE THERAMEX (MC) | 2011-08-18 | — | — | WO | disclosed |
| EP-2354150-A1 | Process for the preparation of gestodene | LABORATOIRE THERAMEX (MC) | 2011-08-10 | — | — | EP | disclosed |
| EP-0538348-B1 | UNSATURATED 15-DEHYDRO-17alpha-CYANOMETHYL-17beta- HYDROXYSTEROIDS | JENAPHARM GMBH (DE) | 1996-10-02 | — | — | EP | disclosed |
| JP-H07316184-A | 3-ALKOXY-18-METHYL-3,5-ESTRADIEN-17-ONE | SCHERING AG | 1995-12-05 | — | — | JP | disclosed |
| US-5438134-A | Endocrine disorders, reproductive control | JENAPHARM GMBH (DE) | 1995-08-01 | — | — | US | disclosed |
| EP-0538348-A1 | PROCESS FOR PRODUCING UNSATURATED 17-ALPHA-CYANOMETHYL-17-BETA-HYDROXYSTEROIDS. | JENAPHARM GMBH (DE) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000991-A1 | PROCESS FOR PRODUCING UNSATURATED 17-ALPHA-CYANOMETHYL-17-BETA-HYDROXYSTEROIDS | JENAPHARM GMBH (DE) | 1992-01-23 | — | — | WO | disclosed |
| EP-0201452-B1 | PROCESS FOR THE PREPARATION OF 17-ALPHA-ETHYNYL-17-BETA-HYDROXY-18-METHYL-ESTRA-4,15-DIEN-3-ONE AND THE STARTING PRODUCTS FOR THIS PROCESS | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-08-09 | — | — | EP | disclosed |
| US-4719054-A | Process for the production of 17α-ethynyl-17β-hydroxy-18-methyl-4,15-estradien-3-one, and novel 3,5-estradien-17-one starting compounds for this process | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-01-12 | — | — | US | disclosed |
| EP-0201452-A2 | Process for the preparation of 17-alpha-ethynyl-17-beta-hydroxy-18-methyl-estra-4,15-dien-3-one and the starting products for this process | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137885-A1 | PROCESS FOR INTRODUCING A DOUBLE BOND INTO POSITION 15, 16 OF A STEROID | CYP17A1, NR5A1, HSD17B7 | SRD5A2 8/4885AR 89/4885PGR 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.